Treating inflammation by blocking interleukin-1 in humans
Open accessThe DOI matches its Crossref record; 258 of the 258 references it cites were found in a registry or an index.
Abstract
IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL-1-mediated inflammation. Although IL-1, either IL-1α or IL-1β, was administered to patients in order to improve bone marrow function or increase host immune responses to cancer, these patients experienced unacceptable toxicity with fever, anorexia, myalgias, arthralgias, fatigue, gastrointestinal upset and sleep disturbances; frank hypotension occurred. Thus it was not unexpected that specific pharmacological blockade of IL-1 activity in inflammatory diseases would be beneficial. Monotherapy blocking IL-1 activity in a broad spectrum of inflammatory syndromes results in a rapid and sustained reduction in disease severity. In common conditions such as heart failure and gout arthritis, IL-1 blockade can be effective therapy. Three IL-1blockers have been approved: the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the activity of IL-1α and IL-1β. A soluble decoy receptor, rilonacept, and a neutralizing monoclonal anti-interleukin-1β antibody, canakinumab, are also approved. A monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α are in clinical trials. By specifically blocking IL-1, we have learned a great deal about the role of this cytokine in inflammation but equally important, reducing IL-1 activity has lifted the burden of disease for many patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Self-citationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
McDermott, M. F., Aksentijevich, I., Galon, J., McDermott, E. M., Ogunkolade, B. W., Centola, M., Mansfield, E., Gadina, M., Karenko, L., Pettersson, T., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80721-7 · Cited by 1,408
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Cited by
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Self-citationChamorro, Á., Dirnagl, U., Urra, X., & Planas, A. M. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00114-9 · Cited by 1,198
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
Jiang, H., He, H., Chen, Y., Huang, W., Cheng, J., Ye, J., Wang, A., Tao, J., Wang, C., Liu, Q., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171419 · Cited by 748
Pharmacological Inhibitors of the NLRP3 Inflammasome
Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02538 · Cited by 671
The NLRP3 inflammasome in acute myocardial infarction
Toldo, S., & Abbate, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.161 · Cited by 665
The role of interleukin-1 in general pathology
Kaneko, N., Kurata, M., Yamamoto, T., Morikawa, S., & Masumoto, J. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0101-5 · Cited by 617
Littlewood-Evans, A., Sarret, S., Apfel, V., Loesle, P., Dawson, J., Zhang, J., Muller, A., Tigani, B., Kneuer, R., Patel, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160061 · Cited by 514
Bhol, N. K., Bhanjadeo, M. M., Singh, A. K., Dash, U. C., Ojha, R. R., Majhi, S., Duttaroy, A. K., & Jena, A. B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117177 · Cited by 514
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H., Callahan, M., Wolchok, J. D., Halaban, R., Dhodapkar, M. V., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401686 · Cited by 461
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Ito, M., Shichita, T., Okada, M., Komine, R., Noguchi, Y., Yoshimura, A., & Morita, R. (2015) · Nature Communications · doi:10.1038/ncomms8360 · Cited by 412
Immune crosstalk in cancer progression and metastatic spread: a complex conversation
Garner, H., & de Visser, K. E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0271-z · Cited by 395
The family of the interleukin‐1 receptors
Boraschi, D., Italiani, P., Weil, S., & Martin, M. U. (2018) · Immunological Reviews · doi:10.1111/imr.12606 · Cited by 389
The Gasdermin‐D pore acts as a conduit for IL‐1β secretion in mice
Heilig, R., Dick, M. S., Sborgi, L., Meunier, E., Hiller, S., & Broz, P. (2018) · European Journal of Immunology · doi:10.1002/eji.201747404 · Cited by 377
Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury
Toldo, S., Mauro, A. G., Cutter, Z., & Abbate, A. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00158.2018 · Cited by 369
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
Petrovsky, N. (2015) · Drug Safety · doi:10.1007/s40264-015-0350-4 · Cited by 366
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 366
Self-citationPyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment
Alavi, A., French, L. E., Davis, M. D., Brassard, A., & Kirsner, R. S. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0251-7 · Cited by 321
Exosome-like Nanoparticles from Ginger Rhizomes Inhibited NLRP3 Inflammasome Activation
Chen, X., Zhou, Y., & Yu, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00246 · Cited by 311
Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review
Cheng, R., Wu, Z., Li, M., Shao, M., & Hu, T. (2020) · International Journal of Oral Science · doi:10.1038/s41368-019-0068-8 · Cited by 298
The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ
Zheng, C., Zhou, X.-W., & Wang, J.-Z. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0054-4 · Cited by 292
An inherited mutation in NLRC4 causes autoinflammation in human and mice
Kitamura, A., Sasaki, Y., Abe, T., Kano, H., & Yasutomo, K. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141091 · Cited by 285
Interleukin-1 function and role in rheumatic disease
Schett, G., Dayer, J.-M., & Manger, B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.166 · Cited by 279
Inhibition of double‐strand DNA‐sensing cGAS ameliorates brain injury after ischemic stroke
Li, Q., Cao, Y., Dang, C., Han, B., Han, R., Ma, H., Hao, J., & Wang, L. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911002 · Cited by 273
Winthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases
Liu, D., Zeng, X., Li, X., Mehta, J. L., & Wang, X. (2018) · Basic Research in Cardiology · doi:10.1007/s00395-017-0663-9 · Cited by 258
Binder, S., Luciano, M., & Horejs-Hoeck, J. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.08.004 · Cited by 190
Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation
Barchetta, I., Cimini, F. A., Ciccarelli, G., Baroni, M. G., & Cavallo, M. G. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01052-3 · Cited by 77
Treating Pulmonary Silicosis by Blocking Interleukin 1
Cavalli, G., Fallanca, F., Dinarello, C. A., & Dagna, L. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2150le · Cited by 56
Self-citation
Metadata
- Authors
- Dinarello, C. A., & van der Meer, J. W. M.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 25
- Issue
- 6
- Pages
- 469-484
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W2124335748
- Cited by
- 549
- References
- 258
- FWCI
- 17.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.